Aurinia Launches Its First Drug With Lupkynis Approval For Lupus Nephritis

 
• By Jessica Merrill

The calcineurin inhibitor, only the second drug to be approved by the US FDA for lupus nephritis, will be competing against GlaxoSmithKline’s Benlysta.

Nature background concept: Alone tree on meadow sunset.
Aurinia is launching its first commercial drug and doing it independently • Source: Shutterstock

More from Immunological

More from Therapy Areas